| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8780279 | Gynecologic Oncology | 2018 | 8 Pages |
Abstract
Addition of intermittent or continuous linsitinib with paclitaxel did not improve outcomes in patients with platinum-resistant/refractory ovarian cancer compared with paclitaxel alone.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Amit Oza, Stanley Kaye, Jan Van Tornout, Cristiana Sessa, Martin Gore, R. Wendel Naumann, Hal Hirte, Nicoletta Colombo, Jihong Chen, Seema Gorla, Srinivasu Poondru, Margaret Singh, Joyce Steinberg, Geoff Yuen, Susana Banerjee,